Pfizer reported positive Phase 3 results for TALZENNA (talazoparib) in combination with XTANDI in HRR gene mutated metastatic castration sensitive prostate cancer. The company plans to seek expanded ...
Pfizer Inc. PFE on Tuesday announced topline results from the Phase 2 FOURLIGHT-1 study in pretreated metastatic breast ...
A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...
Pfizer Inc. PFE shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic ...
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
They aren't just "pandemic stocks." ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating ...
A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...
The drug, which one analyst described as a “critical” part of Pfizer’s oncology strategy, represents a possible improvement upon Ibrance and other, similar breast cancer medicines from Eli Lilly and ...
Pfizer said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive ...
Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.
Pfizer's CEO said Sunday that the company is "days" away from submitting data to the FDA in the hopes of having its COVID-19 vaccine approved for children as young as 5. In speaking ABC News on Sunday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results